1-3 of 3
Patrick P Ng, PhD
Close
Sort by
Journal Articles

The ITK Inhibitor Cpi-818 Blocks Activation of T Cells from Autoimmune Lymphoproliferative Syndrome (ALPS) Patients and Is Active in a Murine Model of ALPS

V. Koneti Koneti Rao, MD FRCPA, Patrick P. Ng, PhD, Craig M. Hill, PhD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
https://doi.org/10.1182/blood-2020-137631
Published: 2020
Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1571.
https://doi.org/10.1182/blood-2019-127338
Published: 2019
Journal Articles

Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy

James A Torchia, Patrick P Ng, PhD, Homer Chen, Holbrook E Kohrt, MD, PhD, Aurelien Marabelle, MD, MSc, Ash A. Alizadeh, MD, PhD, Ronald Levy, MD
Journal: Blood
Blood (2012) 120 (21): 3713.
https://doi.org/10.1182/blood.V120.21.3713.3713
Published: 2012